Search

Issue
Title
Authors
Vol 26, No 1 (2024)
Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study
Zhukova L.G., Bolotina L.V., Dvornichenko V.V., Fadeeva N.V., Ganshina I.P., Grechukhina K.S., Hasanova A.I., Kislov N.V., Kudryavtsev I.Y., Manikhas A.G., Musaeva N.E., Nizhegorodtseva A.A., Sadikova O.E., Sakaeva D.D., Snegovoy A.V., Stroyakovskiy D.L., Tjulandin S.A., Trishkina E.A., Vladimirova L.I., Volkov N.M., Kostalanova Y.V.
PDF
(Rus)
Vol 25, No 1 (2023)
Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review
Kolyadina I.V.
PDF
(Rus)
Vol 26, No 2 (2024)
Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
Grechukhina K.S., Filonenko D.A., Sukhova M.V., Zhukova L.G.
PDF
(Rus)
Vol 23, No 1 (2021)
Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
Board E.
PDF
(Rus)
Vol 23, No 1 (2021)
Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
Board E.
PDF
(Rus)
Vol 22, No 2 (2020)
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
Kolyadina I.V., Ganshina I.P., Kuzmicheva S.V., Tekeeva A.I., Kolokolov J.D., Volkonskii M.V., Poddubnaya I.V.
PDF
(Rus) PDF
(Eng)
Vol 16, No 3 (2014)
Personalized approach to HER2-positive advanced breast cancertherapy
Stenina M.B.
Vol 16, No 3 (2014)
Modern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal women
Jackisch C., Llombart-Cussac A.
Vol 23, No 2 (2021)
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
Board E.
PDF
(Rus)
1 - 9 of 9 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies